Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01894594 · ClinicalTrials.gov registry record · Phase 1
Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease
A Phase 1 study, sponsored by University Hospitals Cleveland Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT01894594 is a Phase 1 study that was terminated before completion, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 7 participants.
The verdict
NCT01894594, a Phase 1 study, was terminated before completion, sponsored by University Hospitals Cleveland Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The objective of this study is to assess the effect of alkali administration on bicarbonate and potassium levels in patients with Sickle Cell Disease (SCD) and depressed serum bicarbonate levels. The study is a prospective non-blinded evaluation of tolerability and efficacy of alkali repletion with 4 weeks of observation and two sequential 4 week courses of escalating oral sodium bicarbonate treatment.
Interventions
- DRUG Sodium Bicarbonate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2013-06 |
| Est. Completion | 2019-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01894594
The ClinicalTrials.gov registry entry for NCT01894594 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sodium Bicarbonate is the first listed.
NCT01894594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01894594 about?
NCT01894594 is a clinical study titled "Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease". The objective of this study is to assess the effect of alkali administration on bicarbonate and potassium levels in patients with Sickle Cell Disease (SCD) and depressed serum bicarbonate levels. The study is a prospective non-blinded evaluation of tolerability and efficacy of alkali repletion with ...
What is the current status of trial NCT01894594?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2013-06. Estimated completion is 2019-03.
What interventions are being tested in trial NCT01894594?
The interventions under investigation include: Sodium Bicarbonate (DRUG).
Who is sponsoring clinical trial NCT01894594?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.